SCHEDULE: ING Entities Report Zero Beneficial Ownership in Tenax Therapeutics

ING Groep N.V. and ING Capital Markets LLC have filed a Schedule 13G, confirming they beneficially own 0% of Tenax Therapeutics, Inc. common stock as of September 11, 2026.

Summary

• ING Groep N.V. and ING Capital Markets LLC have filed an amendment to their Schedule 13G filing.
• As of September 11, 2026, neither ING Groep N.V. nor ING Capital Markets LLC beneficially owned any shares of Tenax Therapeutics, Inc. common stock.
• This filing confirms a 0% ownership stake for both entities in the company's common stock.
• The filing is based on the issuer's reported 37,423,917 shares of common stock outstanding as of July 28, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a neutral filing, primarily confirming a lack of beneficial ownership, which does not provide new positive or negative information about the company's performance or prospects.

Positives

• Confirmation of zero beneficial ownership by ING entities suggests no immediate intent to influence or control Tenax Therapeutics.
• The filing is current and adheres to regulatory requirements.

Negatives

• The filing provides no new financial or operational information about Tenax Therapeutics, offering no insight into the company's performance.
• The lack of any significant stake by a financial institution like ING could be interpreted neutrally or slightly negatively if investors were anticipating institutional interest.

Risks

• The filing itself does not present new risks to Tenax Therapeutics; it merely reports the ownership status of ING entities.
• Potential future changes in ING's ownership, if any, would be subject to separate filings.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Tenax Therapeutics' future performance. It solely addresses the ownership status of ING entities.

Management Comments

• "Based on the 37,423,917 shares of common stock of the issuer (the 'Common Stock') as of July 28, 2026, as reported in the issuer's Quarterly Report on Form 10-Q for the period ended in June 30, 2026, filed with the Securities and Exchange Commission on July 31, 2026."
• "As of September 11, 2026, none of the Reporting Persons beneficially owned any Common Stock."
• "As of September 11, 2026, none of the Reporting Persons beneficially owned any percentage of the Common Stock issued and outstanding as of July 28, 2026..."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and other entities that acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. This particular filing indicates that ING entities do not meet that threshold, or have reduced their holdings below it, which is a common occurrence in the financial markets.

Stakeholder Impact

• Shareholders: No direct impact as this filing confirms a lack of significant ownership by ING, thus no immediate change in control or influence is indicated.
• Management: No impact as the filing does not pertain to internal company operations or strategy.
• Creditors: No impact as the filing does not relate to the company's financial health or debt obligations.

Next Steps

• ING entities will continue to monitor their ownership levels in Tenax Therapeutics and file amendments to Schedule 13G as required by SEC regulations.
• Tenax Therapeutics will continue its business operations as outlined in its previous filings.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Tenax Therapeutics, ING Groep N.V., ING Capital Markets LLC, Ownership Filing, SEC Filing